CHAPTER 1 ABOUT THIS PROFILE 2
Executive summary 2
Quarterly news update 2
Company introduction 2
Company sales 2
Company financials 2
Key products and competitors 3
Data sourcing 3
Sales data 3
Analyst consensus 3
CHAPTER 2 EXECUTIVE SUMMARY 4
Key findings 4
Prescription pharmaceutical sales performance, 2001-13 5
Servier: PharmaVitae forecasts at a glance 6
Strategic insight 7
Focussed player 7
1) Small molecule portfolio... 7
2) ... for cardiovascular indications 8
3) Geographic focus avoids US competition 9
Servier is prepared for a growing generics market 9
French generics market to expand due to healthcare cost pressures 10
Generic pricing will impact extent of Biogaran's growth 11
SWOT analysis 12
Strengths 12
Weaknesses 13
Opportunities 14
Threats 14
CHAPTER 3 QUARTERLY NEWS UPDATE 19
Product developments 19
Deals and alliances 20
Product deals 20
Technology deals 21
M&A activity 21
Company announcements 22
Future product milestones 22
CHAPTER 4 COMPANY INTRODUCTION 23
Key findings 23
Background 24
Key corporate developments 24
M&A history 25
Limited history of M&A prior to mid-1990s 25
Egis acquisition opens door to RoW markets 25
Current corporate structure 26
Branded pharmaceuticals 26
Generic pharmaceuticals 27
CHAPTER 5 COMPANY SALES 28
Key findings 28
Prescription pharmaceutical sales and growth rate analysis, 2001-13 29
Product analysis 31
Product analysis, 2001-07 31
Product analysis, 2007-13 35
Therapy area analysis 38
Therapy area analysis, 2001-07 39
Therapy area analysis, 2007-13 42
Therapy area focus, 2001-13 45
Geographic analysis 47
Geographic analysis, 2001-07 48
Geographic analysis, 2007-13 51
Geographic focus, 2001-13 53
Launch/core/expiry analysis 55
Explanation of launch/core/expiry analysis 55
Launch analysis, 2007-13 56
Core analysis, 2007-13 59
Expiry analysis, 2007-13 62
Launch/core/expiry configuration, 2007-13 64
Molecule type analysis 66
Molecule type analysis, 2001-07 67
Molecule type analysis, 2007-13 67
Externalization analysis 69
Externalization analysis, 2001-07 70
Externalization analysis, 2007-13 72
CHAPTER 6 COMPANY FINANCIALS 74
Key findings 74
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07 75
CHAPTER 7 KEY PRODUCTS AND COMPETITORS 76
Key findings 76
Overview 77
Cardiovascular 78
Coversyl 78
Overview 78
Sales forecast 79
Bipreterax 82
Overview 82
Sales forecast 83
Vastarel 85
Overview 85
Sales forecast 86
Daflon 88
Overview 88
Sales forecast 89
Natrilix 91
Overview 91
Sales forecast 92
Procoralan 94
Overview 94
Sales forecast 95
Triplion 97
Overview 97
Sales forecast 98
Hyperium 100
Overview 100
Sales forecast 101
Endocrine, metabolic and genetic disorders 102
Diamicron 102
Overview 102
Sales forecast 103
Musculoskeletal 105
Protelos 105
Overview 105
Sales forecast 106
Central Nervous System 109
Valdoxan 109
Overview 109
Sales forecast 110
Respiratory 112
Pneumorel 112
Overview 112
Sales forecast 113
Gastroenterology 114
Omeprazole 114
Overview 114
Sales forecast 115
CHAPTER 8 APPENDIX 117
R&D pipeline 117
References 118
Abbreviations 119
Exchange rates 120
List of Tables
Table 1: Servier - PharmaVitae forecasts at a glance 6
Table 2: Servier key product developments, 2008 19
Table 3: Servier product deals and alliances, 2008 20
Table 4: Servier technology deals and alliances, 2008 21
Table 5: Servier M&A activity, 2008 21
Table 6: Servier company announcements, 2008 22
Table 7: Servier future product milestones, 2008-10 22
Table 8: Servier product portfolio overview ($m), 2001-07 31
Table 9: Servier product portfolio overview ($m), 2007-13 35
Table 10: Servier product portfolio overview ($m), 2001-07 39
Table 11: Servier product portfolio overview ($m), 2007-13 42
Table 12: Servier portfolio overview by geographic region ($m), 2001-07 48
Table 13: Servier portfolio overview by geographic region ($m), 2007-13 51
Table 14: Servier launch portfolio overview ($m), 2007-13 56
Table 15: Servier core portfolio overview ($m), 2007-13 59
Table 16: Servier expiry portfolio overview ($m), 2007-13 62
Table 17: Servier portfolio overview by molecule type ($m), 2001-07 67
Table 18: Servier product portfolio overview by molecule type ($m), 2007-13 67
Table 19: Servier product portfolio overview by source ($m), 2001-07 70
Table 20: Servier product portfolio overview by source ($m), 2007-13 72
Table 21: Total Servier sales by business unit ($m), 2001-07 75
Table 22: Key products overview 77
Table 23: Coversyl: overview 78
Table 24: Coversyl: sales forecast ($m), 2007-13 79
Table 25: Bipreterax: overview 82
Table 26: Bipreterax: sales forecast ($m), 2007-13 83
Table 27: Vastarel: overview 85
Table 28: Vastarel: sales forecast ($m), 2007-13 86
Table 29: Daflon: overview 88
Table 30: Daflon: sales forecast ($m), 2007-13 89
Table 31: Natrilix: overview 91
Table 32: Natrilix: sales forecast ($m), 2007-13 92
Table 33: Procoralan: overview 94
Table 34: Procoralan: sales forecast ($m), 2007-13 95
Table 35: Triplion: overview 97
Table 36: Triplion: sales forecast ($m), 2007-13 98
Table 37: Hyperium: overview 100
Table 38: Hyperium: sales forecast ($m), 2007-13 101
Table 39: Diamicron: overview 102
Table 40: Diamicron: sales forecast ($m), 2007-13 103
Table 41: Protelos: overview 105
Table 42: Protelos: sales forecast ($m), 2007-13 106
Table 43: Valdoxan: overview 109
Table 44: Valdoxan: sales forecast ($m), 2007-13 110
Table 45: Pneumorel: overview 112
Table 46: Pneumorel: sales forecast ($m), 2007-13 113
Table 47: Omeprazole: overview 114
Table 48: Omeprazole: sales forecast ($m), 2007-13 115
Table 49: Servier's R&D pipeline (Phase I-registration) 117
Table 50: Exchange rates, 2007 120
List of Figures
Figure 1: Servier prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 5
Figure 2: Servier market positioning, 2001-13 7
Figure 3: French ACE inhibitor market* in 2007, market share by Company and product type (%) 8
Figure 4: Servier prescription pharmaceutical sales, by Generic Rx and Branded Rx products ($m), 2001-13 10
Figure 5: Servier SWOT analysis 12
Figure 6: Servier, key corporate developments 24
Figure 7: Servier, corporate structure 26
Figure 8: Servier prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 29
Figure 9: Servier key sales growth driver & resistors ($m), 2001-07 32
Figure 10: Servier key sales growth drivers & resistors ($m), 2007-13 36
Figure 11: Servier prescription pharmaceutical sales by therapy area ($m), 2001-13 38
Figure 12: Servier prescription pharma sales by therapy area (% of total), 2001-13 45
Figure 13: Servier prescription pharmaceutical sales by geographic region ($m), 2001-13 47
Figure 14: Servier growth drivers and resistors by geographic region ($m), 2001-07 49
Figure 15: Servier drivers and resistors by geographic region ($m), 2007-13 51
Figure 16: Servier prescription pharmaceutical sales by geographic region (% of total), 2001-13 53
Figure 17: French ACE inhibitor market* in 2007, market share by company and product type (%) 54
Figure 18: Servier launch/core/expiry configuration ($m), 2007-13 64
Figure 19: Servier prescription pharmaceutical sales by molecule type ($m), 2001-13 66
Figure 20: Servier growth drivers and resistors by molecule type ($m), 2007-13 68
Figure 21: Servier prescription pharmaceutical sales by source ($m), 2001-13 69
Figure 22: Servier growth drivers and resistors by source ($m), 2001-07 70
Figure 23: Servier growth drivers and resistors by source ($m), 2007-13 73